Study summary
Most responses to teprotumumab lasted more than a year after treatment ended
67.9%still had a proptosis response at week 72
What was tested
Follow-up of people who responded to teprotumumab in three clinical trials, tracked up to 72 weeks and beyond.
What they found
- At week 72, 67.9% still had a proptosis response and 72.9% a double-vision response.
- Only 17.9% needed additional TED treatment over about 2 years.
What it means
Suggests a single course gives lasting benefit for most, though some relapse.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.